Bio-Path Holdings
  • About Bio-Path
    • Overview
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Partnering Opportunities
  • Technology
  • Pipeline
    • Pipeline
    • Prexigebersen
    • BP1001-A
    • BP1002
    • BP1003
  • Patients
  • Investors
    • Overview
    • SEC Filings
    • Corporate Governance
  • Media
    • Press Releases
    • Events
    • Presentations & Publications
  • Careers
  • Contact Us

Bio-Path Holdings Provides Update from Phase 1/1b Clinical Trial of BP1002 for Treatment of Refractory/Relapsed Acute Myeloid Leukemia

BP1002_RR_AML_4th_Dose_Cohort_and_Significant_Patient_Response

Bio-Path Holdings

All Rights Reserved

Office:

4710 Bellaire Blvd, Suite 210
Bellaire, TX 77401

T: (832) 742-1357

R&D:

5455 Dashwood Street, Suite 300
Bellaire, TX 77401

T: (832) 742-1357

logo
  • About Bio-Path
    • Overview
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Partnering Opportunities
  • Technology
  • Pipeline
    • Pipeline
    • Prexigebersen
    • BP1001-A
    • BP1002
    • BP1003
  • Patients
  • Investors
    • Overview
    • SEC Filings
    • Corporate Governance
  • Media
    • Press Releases
    • Events
    • Presentations & Publications
  • Careers
  • Contact Us